Participants in a clinical trial who used Belhaven Biopharma’s Nasdepi dry powder epinephrine nasal spray experienced positive outcomes…
A growing number of companies are developing alternatives ranging from nasal powders and sprays to a film or liquid administered under the tongue…
Belhaven Biopharma today issued a corporate update announcing key milestones that together materially advance the company’s path to commercialization and partnership for Nasdepi®
Belhaven Biopharma, a leader in developing innovative intranasal products for emergency use, today announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has accepted their IND application for Nasdepi®
Belhaven Biopharma, a clinical-stage biopharmaceutical company advancing innovative dry powder nasal drug delivery solutions,
Belhaven Biopharma, a leader in innovative treatments for severe allergic reactions, is pleased to share promising results from its dose confirmational clinical trial of Nasdepi®
“This next clinical study is a crucial step in confirming the safety, efficacy, and bioavailability of Nasdepi® as demonstrated in our earlier trial and in comparison to traditional autoinjectors,”
The data supports Nasdepi® as a viable alternative to epinephrine autoinjectors and other liquid formulations, particularly in settings where storage and distribution are challenges.
Belhaven Biopharma, a leader in innovative treatments for severe allergic reactions, today shared promising results from its Phase 1 clinical trial of…..
Belhaven BioPharma has developed a new delivery system for epinephrine that is more efficient, convenient, stable, and less expensive than an EpiPen…..
The North Carolina Biotechnology Center awarded 19 grants and loans totaling more than $2.3 million to universities, bioscience companies and ……..
The North Carolina Biotechnology Center awarded 21 grants and loans totaling more…
Biopharma, a leader in dry powder nasal drug delivery technologies and emergency treatments, is proud to announce that its innovative intranasal epinephrine product……
Belhaven Biopharma, a leader in nasal drug delivery technologies and emergency allergy care solutions, is set to present new clinical data from its Phase…..
Belhaven Biopharma’s Nasdepi®, a finalist for the 2024 Fierce Innovation Awards, showcases breakthroughs in emergency drug delivery.